Sunday 18 October 2026
Export BLSM’s income statement to Excel — free account
BlossomHill Therapeutics, Inc.
BLSM
Insiders bought in the last twelve months.
13.94
1.04
−6.94%
Follow BLSM
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
15.38 | 8.97 |
Net Debt/EBITDA |
2.78 | 2.15 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
1.02 | 0.77 |
Capex/Depreciation |
(0.26) | (2.42) |
| 0.00% | 59.19% | |
| 0.00% | (44.90%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(31.16%) | (48.42%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(13.76) | (19.68) |
Cash per Share |
43.73 | 56.06 |
Shareholders Equity per Share |
43.67 | 51.31 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
43.67 | 51.31 |
Free Cash Flow |
(31.51) | (47.99) |
Working Capital |
97.40 | 123.35 |
Capital Expenditures |
(0.09) | (1.07) |
Net Current Asset Value |
97.40 | 100.95 |
| Other line items | ||
Quick Ratio |
14.79 | 8.83 |
Depreciation/Fixed assets |
0.32 | 0.26 |
Cash ROIC |
(15.74%) | (18.33%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(13.72) | (19.25) |
Capex per Share |
(0.04) | (0.44) |
Average Payables |
— | 1.58 |
Average Assets |
— | 134.87 |
Average Common Equity |
— | (102.31) |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026